Ashlyna 91 Day Shortage: What Providers and Prescribers Need to Know in 2026

Extended-cycle oral contraceptives have become a staple in reproductive healthcare. Ashlyna 91 Day — the generic equivalent of Seasonique — is one of the most commonly prescribed options. But if your patients are reporting difficulty filling their prescriptions, you're not imagining the problem.

This briefing covers the current state of Ashlyna availability, what's driving the supply challenges, prescribing alternatives, cost and access considerations, and tools you can use to help your patients.

Current Status and Timeline

As of early 2026, Ashlyna 91 Day (Levonorgestrel 0.15 mg / Ethinyl Estradiol 0.03 mg and Ethinyl Estradiol 0.01 mg, manufactured by Glenmark Generics) is not listed on the FDA Drug Shortage Database. However, real-world availability remains inconsistent across regions and pharmacy chains.

The situation has evolved in phases:

• 2022–2023: Post-Dobbs demand shifts increased patient interest in long-supply contraceptive options, including extended-cycle OCs. Manufacturing did not immediately scale to meet demand.
• 2024: Broader pharmaceutical supply chain improvements helped some generics stabilize, but extended-cycle formulations with limited manufacturers continued to face intermittent gaps.
• 2025–2026: Supply has improved overall, but Ashlyna specifically — with Glenmark as the primary manufacturer — experiences periodic availability issues at individual pharmacy locations.

Prescribing Implications

When patients report that they cannot fill an Ashlyna prescription, providers should consider the following:

Therapeutic Equivalence

Several medications are therapeutically equivalent to Ashlyna and can be prescribed as direct substitutes:

• Amethia — identical formulation (Levonorgestrel 0.15/0.03 + EE 0.01), different manufacturer
• Camrese — brand-name equivalent (same as Seasonique)
• Daysee — another extended-cycle generic with the same active ingredients

For patients who are willing to accept a slightly different formulation:

• Jolessa or Quasense — generics of Seasonale; same 84 active tablets but with 7 placebo pills instead of low-dose EE. Patients may experience more breakthrough bleeding but contraceptive efficacy is equivalent.

Writing Flexible Prescriptions

Consider prescribing by generic name (Levonorgestrel/Ethinyl Estradiol extended-cycle 0.15/0.03 and 0.01) and adding "or generic equivalent" to allow pharmacists flexibility in dispensing whichever brand is currently in stock. This can prevent patients from making multiple pharmacy visits.

Proactive Communication

When prescribing extended-cycle OCs, consider advising patients to:

• Refill 1–2 weeks before running out
• Use Medfinder for Providers to check pharmacy availability
• Have a backup plan (alternative medication or temporary 28-day pill)

Availability Picture

Availability varies significantly by geography and pharmacy type:

• Chain pharmacies (CVS, Walgreens, Rite Aid): Most likely to experience stock-outs due to centralized purchasing and high patient volume.
• Independent pharmacies: Often have more flexibility to source from multiple wholesalers and may have better availability.
• Mail-order pharmacies: Generally reliable for 90-day supplies and may have better stock consistency.
• Health system pharmacies: Availability depends on formulary decisions and purchasing contracts.

The Medfinder provider dashboard can help you check real-time availability at pharmacies near your patients before writing a prescription.

Cost and Access Considerations

Contraceptive access and affordability directly impact adherence. Key cost factors for Ashlyna 91 Day:

• Insured patients (ACA-compliant plans): $0 copay for generic OCs under the contraceptive mandate.
• Uninsured or underinsured patients: Retail price ranges from $200–$400 per 91-day pack without discount programs.
• With discount cards (GoodRx, SingleCare): As low as $20–$35 per pack.
• Title X clinics and Planned Parenthood: May provide free or low-cost contraceptives regardless of insurance status.
• Patient assistance programs: NeedyMeds and RxAssist maintain databases of available programs, though Glenmark does not currently offer a dedicated Ashlyna savings card.

For a detailed patient-facing resource on savings options, see our guide: How to Save Money on Ashlyna 91 Day.

Tools and Resources for Your Practice

• Medfinder for Providers — Check real-time pharmacy availability for Ashlyna and alternatives. Share results with patients or integrate into your referral workflow.
• FDA Drug Shortage Database — Monitor for formal shortage listings at accessdata.fda.gov.
• ASHP Drug Shortage Resource Center — Additional shortage monitoring and alternative therapy recommendations.
• Pharmacy benefit verification — When switching patients between generics, confirm the alternative is on the patient's formulary to prevent unexpected out-of-pocket costs.

Looking Ahead

The extended-cycle oral contraceptive market remains relatively concentrated, with a limited number of manufacturers producing these formulations. Until additional manufacturers enter the market or existing production capacity increases, periodic availability issues are likely to continue.

Providers can mitigate the impact on patients by:

• Writing prescriptions by generic name with flexibility for equivalent substitution
• Maintaining awareness of alternative formulations
• Directing patients to availability tools like Medfinder
• Considering telehealth follow-ups for prescription adjustments when patients report difficulty filling

Final Thoughts

Ashlyna 91 Day remains an effective and popular extended-cycle contraceptive, but real-world availability doesn't always match demand. As a provider, your awareness of the supply landscape and willingness to prescribe flexible alternatives can make a significant difference in your patients' continuity of care.

For additional patient resources, share these guides:
Why Is Ashlyna 91 Day So Hard to Find?
How to Find Ashlyna 91 Day in Stock
Alternatives to Ashlyna 91 Day